Horizon Europe Avrupa Birliği
Neutral-Atom Platform Technologies
This action aims to establish European leadership in neutral-atom quantum simulation and digital quantum computing by delivering: • Fully programmable industry-ready quan…
Horizon Europe · Avrupa Birliği
Improving equitable health outcomes and added value for and with cancer patients through health-economics…
Full title in the source: Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes research
10 Şubat 2027 tarihinde açılıyor
AB Ufuk Avrupa programı tarafından 3 hibe bekleniyor; proje başına €5 milyon – €7 milyon; toplam bütçe €10 milyon. Başvurular 16 Eylül 2027 tarihinde kapanıyor (AB çağrıları genellikle Brüksel saatiyle 17:00’de kapanır). AB üye ülkelerindeki ve Türkiye gibi ortak ülkelerdeki kuruluşlar genellikle katılabilir; konu koşulları belirleyicidir.
- Son başvuru
- 16 Eylül 2027 (305 gün kaldı)
- Açılış
- 10 Şubat 2027
- Hibe tutarı
- Proje başına €5 milyon – €7 milyon
- Toplam bütçe
- €10 milyon
- Destek oranı
- Uygun maliyetlerin %100’ü Bu program için standart kural; çağrı farklı olabilir.
- Toplam bütçe
- €10 milyon
- Beklenen hibe sayısı
- 3
- Faaliyet türü
- HORIZON Research and Innovation Actions · HORIZON Lump Sum Grant
- Olası başvuru sahipleri
- Şirketler, KOBİ’ler / girişimler, Kâr amacı gütmeyenler, Üniversiteler ve araştırma, Kamu kurumları Kaynak kategorilerinden veya program kurallarından; uygunluğa çağrı karar verir.
- Fon sağlayıcı
- Horizon Europe (HORIZON)
- Referans
- HORIZON-MISS-2027-02-CANCER-04
- Çağrı
- HORIZON-MISS-2027-02
- Son kontrol
- 14 Kasım 2026
Resmi açıklamalar fon sağlayıcının dilindedir (çoğunlukla İngilizce); bu sayfadaki özet ve temel bilgiler Türkçedir.
Beklenen sonuçlar
Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes:
• People at risk of cancer, cancer patients and their caregivers/families benefit from access to more effective and cost-effective, national or regional, cancer control programmes across EU Member States and Associated Countries.
• Researchers, physicians, innovators [1] , SMEs and other professionals from different disciplines and sectors have access to national, regional or local data on healthcare spending (such as expenditures, resource allocations, organisation and type of healthcare interventions, and for which cancer indications, infrastructure, medical prescriptions, drug pricing, drug sales, reimbursement data from health insurers, population-based cancer registries or other cancer-centred registry data, longitudinal epidemiology data) for research and commercial purposes.
Tam metni oku
• National or regional healthcare systems, healthcare providers, policymakers and authorities in European regions, EU Member States and Associated Countries have the evidence to improve equitable health outcomes of cancer patients by addressing direct and indirect costs, delivering value-driven cancer care and tackling organisational challenges of a rapidly-changing, dynamic cancer control [2] landscape.
Kapsam
Proposals should address all of the following:
• Establish, validate or further refine health-economics research, health systems research, epidemiological or outcomes research methods, models, or modelling to perform (comparative) cost-effectiveness and epidemiological analyses benefiting equitable health outcomes of and added value for people at risk of cancer as well as cancer patients living with and beyond their disease.
• Take into account socio-economic inequalities, socio-demographic, organisational, innovative or cultural trends, socio-cultural or behavioural change (for example in the case of primary prevention or precision medicine) by involving people at risk of cancer or cancer patients and their caregivers/families through research that stimulates social innovation and supports end-user engagement using participative research models.
• Calculate cancer-control related healthcare expenditures [3] and its relation to value-driven healthcare benefitting health outcomes of people at risk of cancer as well as cancer patients living with and beyond their disease, taking into account the needs of the target population and the specificities of healthcare provision at local, regional, or national level, duly reflecting the (cultural) diversity and available resources across EU Member States and Associated Countries.
Tam metni oku
• Improve health outcomes of people at risk of cancer or cancer patients and their caregivers/families living with and beyond their disease, by demonstrating how to improve access to and the organisation of state-of-the-art, evidence-based, cost-effective cancer control programmes in dedicated cancer centres or medical centres, hospitals, at home or in community settings, taking into account the socio-cultural context, harms and benefits, overall survival or quality of life parameters.
The successful proposals are expected to build on resources made available by the Knowledge Centre on Cancer (KCC) to foster EU alignment and coordination [4] .
Successful proposals will be asked to join the 'Understanding' project cluster of the EU Cancer Mission [5] and should include a budget for networking, attendance at meetings and joint activities [6] . The Commission will facilitate coordination of these activities.
[1] Innovators turn research results into new and better services and products, to remain competitive in a global marketplace and to improve the quality of life of Europe’s citizens
[2] cancer control aims to reduce the incidence, morbidity and mortality of cancer and to improve the quality of life of cancer patients in a defined population, through the systematic implementation of evidence-based interventions for prevention, early detection, diagnosis, treatment, and palliative care
[3] Healthcare expenditure statistics - overview - Statistics Explained - Eurostat
[4] Hosted by the European Commission's Joint Research Centre (JRC). Especially through the ’European Guidelines and Quality Assurance Schemes for Breast, Colorectal…
Kimler başvurabilir
Consortium of at least 3 independent legal entities from 3 different EU Member States or associated countries, at least one in a Member State (Horizon Europe standard rule).
Başvuru sahibi kategorileri yalnızca bir başlangıç noktasıdır. Uygunluğa resmi çağrı karar verir.
Konular
Elderly Health inequalities Physical activity/Exercise Public health Quality of health care Quality-of-life Rehabilitation Cancer Pragmatic Clinical trials Psychosocial Support Survivorship
Zamanlama
Single-stage call. Next deadline 2027-09-16. The portal states the exact cut-off time (EU calls usually close at 17:00 Brussels time).
Nasıl başvurulur
- Portaldaki konunun tamamını okuyun: beklenen sonuçlar, kapsam, faaliyet türü ve ülke veya konsorsiyum kısıtlamaları dahil uygunluk koşulları.
- Kuruluşunuzu AB Funding & Tenders Portalına kaydederek her ortak için bir PIC numarası alın.
- İşbirliğine dayalı araştırma ve yenilik projeleri genellikle üç farklı AB üye ülkesi veya ortak ülkeden en az üç bağımsız ortak gerektirir (Türkiye Ufuk Avrupa’ya ortak ülkedir). Bu konudaki kuralı doğrulayın.
- Bölüm A’yı (portalda doldurulan idari formlar ve bütçe) ve Bölüm B’yi (bu faaliyet türü için resmi şablondaki teknik açıklama) hazırlayın.
- Son başvuru günü kapanış saatinden önce portal üzerinden gönderin. Geç başvurular kabul edilmez.
From the call text
- Who can apply
- Not stated in the call text we hold — check the official page
- Company stage
- Not stated in the call text we hold — check the official page
- Single applicant or consortium
- Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
- Where applicants must be based
- Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
- Where to apply
- Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
Resmi kaynaklar
Bu sayfadaki bilgiler resmi kaynaktan alınmıştır ve en son 14 Kasım 2026 tarihinde kontrol edilmiştir. Sonraki değişiklikler dahil, fon sağlayıcının kendi belgeleri her zaman önceliklidir.
Horizon Europe: diğer çağrılar
Horizon Europe Avrupa Birliği
Next-Generation QKD Systems
This action will strengthen Europe's strategic autonomy in quantum-secure communications by advancing core QKD technologies and integration capabilities. Expected results…
Horizon Europe Avrupa Birliği
Quantum Experimental Pilot Lines for Quantum Technologies
This action will strengthen Europe's leadership and strategic autonomy in quantum technologies by advancing experimental pilot line capacities as a vital stepping stone t…
Horizon Europe Avrupa Birliği
Quantum-Testing Infrastructure for Quantum Technologies
This action will establish a pan-European open-access testing and experimentation infrastructure for quantum technologies, enabling systematic validation and certificatio…
Horizon Europe Avrupa Birliği
Superconducting Platform Technologies
This action will consolidate Europe’s position in superconducting quantum computing through: • Establishment of a full-stack superconducting quantum computer aiming at 1.…